Review ArticlesMagnetic Resonance Imaging Assessment After Therapy in Prostate CancerKoopman, Anna G.M.M. MD; Jenniskens, Sjoerd F.M. MD; Fütterer, Jurgen J. MD, PhDAuthor Information Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands. Address correspondence to Anna G.M.M. Koopman, MD, Department of Radiology and Nuclear Medicine, Radboud University Medical Center, P.O. Box 9101 767, 6500 HB Nijmegen, The Netherlands (e-mail: [email protected]). Received 12 November, 2019 Accepted 11 December, 2019 The authors report no conflicts of interest. Topics in Magnetic Resonance Imaging: February 2020 - Volume 29 - Issue 1 - p 47-58 doi: 10.1097/RMR.0000000000000231 Buy Metrics Abstract Prostate cancer is the fifth leading cause of death worldwide. A variety of treatment options is available for localized prostate cancer and may range from active surveillance to focal therapy or whole gland treatment, that is, surgery or radiotherapy. Serum prostate-specific antigen levels are an important tool to monitor treatment success after whole gland treatment, unfortunately prostate-specific antigen is unreliable after focal therapy. Multiparametric magnetic resonance imaging of the prostate is rapidly gaining field in the management of prostate cancer and may play a crucial role in the evaluation of recurrent prostate cancer. This article will focus on postprocedural magnetic resonance imaging after different forms of local therapy in patients with prostate cancer. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.